Program
imzokitug
Also written as “Imzokitug” and “BMS-986340”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms, led by Bristol-Myers Squibb.
Furthest: phase 2, since May 19, 20212 company-led studies, 2 open or runningNext primary completion: Sep 15, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 22 open or running | phase 2since May 19, 2021 | May 19, 2021 | Sep 15, 2028phase 2 · NCT07680764 |
- Named in Bristol-Myers Squibb’s own pipeline as
imzokitug
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2021First study: phase 2 study in Uterine Cervical NeoplasmsFirst studyNCT04895709 · 1,109 planned · United States, Australia, Canada and more
- Jun 26, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07680764 · 160 planned · United States, Argentina, Australia and more
Ahead
- Sep 15, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07680764
- Aug 31, 2031Primary completion: phase 2 study in Uterine Cervical NeoplasmsNCT04895709
TargetBeta
“A human immunoglobulin G1 (IgG1) nonfucosylated (NF) monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, imzokitug targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating reg…”NCIt, read by Claude
“A human immunoglobulin G1 (IgG1) nonfucosylated (NF) monoclonal antibody against C-C-chemokine receptor 8 (CCR8), ”NCIt, by rule
Other programs on CCR8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cafelkibart | Sino Biopharmaceutical | phase 3 | 7 |
| CCR8 Inhibitor IPG7236rule | nanjing-immunophage-biotech-co-ltd | phase 2 | 3 |
| denikitugrule | Gilead Sciences | phase 2 | 3 |
| Anti-CCR8 Antibody-drug Conjugate TAK-188rule | Takeda | phase 2 | 1 |
| Anti-CCR8 Monoclonal Antibody HC006rule | hc-biopharma-inc | phase 1 | 2 |
| azirkitug | AbbVie | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07680764Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Recruiting | Sep 15, 2028 | 160 |
| NCT04895709Uterine Cervical Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Aug 31, 2031 | 1,109 |
How it is read
Names in the registry
- “Imzokitug”, 1 entry
- “BMS-986340”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Uterine Cervical Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.